Thromboxane (CHEM035499)

IdentificationTaxonomyBiological PropertiesPhysical PropertiesToxicity ProfileSpectraConcentrationsLinksReferencesXML
Record Information
Version1.0
Creation Date2016-05-26 05:49:20 UTC
Update Date2016-11-09 01:21:19 UTC
Accession NumberCHEM035499
Identification
Common NameThromboxane
ClassSmall Molecule
Description
Contaminant Sources
  • FooDB Chemicals
Contaminant TypeNot Available
Chemical Structure
Thumb
MOLSDFPDBSMILESInChI
Synonyms
ValueSource
Thromboxane a2HMDB
Chemical FormulaC20H40O
Average Molecular Mass296.531 g/mol
Monoisotopic Mass296.308 g/mol
CAS Registry Number66719-58-2
IUPAC Name(2R,3S)-3-heptyl-2-octyloxane
Traditional Name(2R,3S)-3-heptyl-2-octyl-oxane
SMILESCCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC
InChI IdentifierInChI=1S/C20H40O/c1-3-5-7-9-11-13-17-20-19(16-14-18-21-20)15-12-10-8-6-4-2/h19-20H,3-18H2,1-2H3/t19-,20+/m0/s1
InChI KeyRZWIIPASKMUIAC-VQTJNVASSA-N
Chemical Taxonomy
Description belongs to the class of organic compounds known as thromboxanes. These are eicosanoids structurally characterized by the presence of a 6-member ether containing ring.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassFatty Acyls
Sub ClassEicosanoids
Direct ParentThromboxanes
Alternative Parents
Substituents
  • Thromboxane
  • Oxane
  • Oxacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Organic oxygen compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available
Biological Properties
StatusDetected and Not Quantified
OriginNot Available
Cellular LocationsNot Available
Biofluid LocationsNot Available
Tissue LocationsNot Available
PathwaysNot Available
ApplicationsNot Available
Biological RolesNot Available
Chemical RolesNot Available
Physical Properties
StateNot Available
AppearanceNot Available
Experimental Properties
PropertyValue
Melting PointNot Available
Boiling PointNot Available
SolubilityNot Available
Predicted Properties
PropertyValueSource
Water Solubility1.2e-05 g/LALOGPS
logP8.56ALOGPS
logP7.61ChemAxon
logS-7.4ALOGPS
pKa (Strongest Basic)-4.1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area9.23 ŲChemAxon
Rotatable Bond Count13ChemAxon
Refractivity93.78 m³·mol⁻¹ChemAxon
Polarizability41.15 ųChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Spectra
Spectra
Spectrum TypeDescriptionSplash KeyView
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positivesplash10-0f9l-6890000000-3f997c71bb65094a1825Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, PositiveNot AvailableSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-0002-0090000000-64191400e8b8791d16fbSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-0udj-2590000000-54b3b759c10bf3ea2f7fSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-006x-9640000000-0e1bc8b51f24769887cbSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-0002-0090000000-09bb02afbfa046dee93fSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-0002-1190000000-895c8c2d04b2e1e0853bSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-0ufu-2950000000-96efc7245fc678eba5aeSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-0002-0090000000-2f702178cb616025d7f3Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-0002-0090000000-3898b4de880fccd3483aSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-0532-1590000000-635fc04338e14fb02a30Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-0002-3090000000-403f8185d42305f3e7c6Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-0adm-9240000000-7cc1bf89e8dba2fcce15Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-0abc-9600000000-a52e9c1820684eb7f306Spectrum
Toxicity Profile
Route of ExposureNot Available
Mechanism of ToxicityNot Available
MetabolismNot Available
Toxicity ValuesNot Available
Lethal DoseNot Available
Carcinogenicity (IARC Classification)Not Available
Uses/SourcesNot Available
Minimum Risk LevelNot Available
Health EffectsNot Available
SymptomsNot Available
TreatmentNot Available
Concentrations
Not Available
DrugBank IDNot Available
HMDB IDHMDB0003208
FooDB IDFDB023124
Phenol Explorer IDNot Available
KNApSAcK IDNot Available
BiGG ID39305
BioCyc IDNot Available
METLIN ID415
PDB IDNot Available
Wikipedia LinkThromboxane
Chemspider ID102829
ChEBI ID1221363
PubChem Compound ID114873
Kegg Compound IDC02198
YMDB IDNot Available
ECMDB IDNot Available
References
Synthesis ReferenceNot Available
MSDSNot Available
General References
1. Gurbel PA, Gattis WA, Fuzaylov SF, Gaulden L, Hasselblad V, Serebruany VL, O'Connor CM: Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes? Am Heart J. 2002 Jun;143(6):1068-75.
2. Rocca B, Ciabattoni G, Tartaglione R, Cortelazzo S, Barbui T, Patrono C, Landolfi R: Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost. 1995 Nov;74(5):1225-30.
3. Dong WG, Liu SP, Zhu HH, Luo HS, Yu JP: Abnormal function of platelets and role of angelica sinensis in patients with ulcerative colitis. World J Gastroenterol. 2004 Feb 15;10(4):606-9.
4. van Genderen PJ, Prins FJ, Michiels JJ, Schror K: Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent. Br J Haematol. 1999 Mar;104(3):438-41.
5. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ 2nd, Lawson JA, Brash AR: Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983 Mar;71(3):676-88.
6. Karamouzis M, Langberg H, Skovgaard D, Bulow J, Kjaer M, Saltin B: In situ microdialysis of intramuscular prostaglandin and thromboxane in contracting skeletal muscle in humans. Acta Physiol Scand. 2001 Jan;171(1):71-6.
7. Wacker MJ, Tyburski JB, Ammar CP, Adams MC, Orr JA: Detection of thromboxane A(2) receptor mRNA in rabbit nodose ganglion neurons. Neurosci Lett. 2005 Sep 30;386(2):121-6.
8. Pfister SL, Hughes MJ, Rosolowsky M, Campbell WB: Role of contaminating platelets in thromboxane synthesis in primary cultures of human umbilical vein endothelial cells. Prostaglandins Other Lipid Mediat. 2002 Sep;70(1-2):39-49.
9. Hsu CY, Halushka PV, Hogan EL, Cox RD: Increased thromboxane level in experimental spinal cord injury. J Neurol Sci. 1986 Jul;74(2-3):289-96.
10. Dogne JM, de Leval X, Delarge J, David JL, Masereel B: New trends in thromboxane and prostacyclin modulators. Curr Med Chem. 2000 Jun;7(6):609-28.
11. Habib A, Vezza R, Creminon C, Maclouf J, FitzGerald GA: Rapid, agonist-dependent phosphorylation in vivo of human thromboxane receptor isoforms. Minimal involvement of protein kinase C. J Biol Chem. 1997 Mar 14;272(11):7191-200.
12. Vericel E, Calzada C, Chapuy P, Lagarde M: The influence of low intake of n-3 fatty acids on platelets in elderly people. Atherosclerosis. 1999 Nov 1;147(1):187-92.
13. Conti S, Desideri N, Passaghe S, Castagnoli MN, Cerletti C, Stein ML: Inhibition of thromboxane biosynthesis by 3-pyridinol carboxypentyl ethers substituted with a hydroxylated octyl chain. J Pharm Pharmacol. 1988 Feb;40(2):144-6.
14. Ylikorkala O, Makila UM, Viinikka L: Amniotic fluid prostacyclin and thromboxane in normal, preeclamptic, and some other complicated pregnancies. Am J Obstet Gynecol. 1981 Nov 1;141(5):487-90.
15. Stuart M, Wu J, Sunderji S, Ganley C: Effect of amniotic fluid on platelet thromboxane production. J Pediatr. 1987 Feb;110(2):289-92.
16. Shimura S, Sasaki T, Ishihara H, Satoh M, Masuda T, Sasaki H, Takishima T: [Airway hyperresponsiveness and mucus secretion]. Nihon Kyobu Shikkan Gakkai Zasshi. 1990 Oct;28(10):1299-304.
17. Chehrazi BB, Giri S, Joy RM: Prostaglandins and vasoactive amines in cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 1989 Feb;20(2):217-24.
18. Mello SB, Barros DM, Silva AS, Laurindo IM, Novaes GS: Methotrexate as a preferential cyclooxygenase 2 inhibitor in whole blood of patients with rheumatoid arthritis. Rheumatology (Oxford). 2000 May;39(5):533-6.
19. De La Cruz JP, Villalobos MA, Escalante R, Guerrero A, Arrebola MM, Sanchez de La Cuesta F: Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction. Br J Pharmacol. 2002 Dec;137(7):1082-8.